BACKGROUND:Treatment of inflammatory kidney diseases with systemic high-dose glucocorticoids (GCs) has severe side effects. Liposomal encapsulation could facilitate local delivery of GCs to the inflamed kidney, as liposomes encapsulate their payload until extravasation at sites of inflammation, potentially resulting in local bioactivity. Our aim was to evaluate the ability of liposomes to accumulate locally after renal ischaemia-reperfusion injury in the rat and to study its effect on macrophages.METHODS:In vitro, human macrophages were incubated with fluorescent liposomes, liposomal prednisolone, prednisolone, empty liposomes or saline. Uptake was studied microscopically and treatment effect was assessed by interkeukin 6 (IL-6) enzyme-link...
Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents'...
Atherosclerosis is a lipid-driven inflammatory disease, for which nanomedicinal interventions are un...
Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents'...
OBJECTIVE: To increase the therapeutic activity of glucocorticoids in experimental arthritis by enca...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Clodronate liposomes are bisphosphonates encapsulated by liposomes that are known to induce macropha...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Glucocorticoids can be highly effective in a wide range of inflammatory disorders e.g. rheumatoid ar...
Objective. To investigate whether RGD peptide-exposing long circulating polyethylene glycol (PEG) li...
Atherosclerosis is a lipid-driven inflammatory disease, for which nanomedicinal interventions are un...
Objective. To investigate whether RGD peptide-exposing long circulating polyethylene glycol (PEG) li...
Atherosclerosis is a lipid-driven inflammatory disease, for which nanomedicinal interventions are un...
Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents'...
Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents'...
Arteriovenous fistulas (AVF) for hemodialysis access have a 1-year primary patency rate of only 60%,...
Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents'...
Atherosclerosis is a lipid-driven inflammatory disease, for which nanomedicinal interventions are un...
Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents'...
OBJECTIVE: To increase the therapeutic activity of glucocorticoids in experimental arthritis by enca...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Clodronate liposomes are bisphosphonates encapsulated by liposomes that are known to induce macropha...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Glucocorticoids can be highly effective in a wide range of inflammatory disorders e.g. rheumatoid ar...
Objective. To investigate whether RGD peptide-exposing long circulating polyethylene glycol (PEG) li...
Atherosclerosis is a lipid-driven inflammatory disease, for which nanomedicinal interventions are un...
Objective. To investigate whether RGD peptide-exposing long circulating polyethylene glycol (PEG) li...
Atherosclerosis is a lipid-driven inflammatory disease, for which nanomedicinal interventions are un...
Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents'...
Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents'...
Arteriovenous fistulas (AVF) for hemodialysis access have a 1-year primary patency rate of only 60%,...
Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents'...
Atherosclerosis is a lipid-driven inflammatory disease, for which nanomedicinal interventions are un...
Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents'...